Articles Mentioning Healthcare Stocks

Results 1 - 10 of 432 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Healthcare

Investing | June 11, 2015

3 Things AbbVie Inc.'s Management Wants You to Know

AbbVie's management team had a lot to talk about on their last investor conference call. Here are my three takeaways you need to know when considering the stock for investment.

Investing | April 25, 2015

3 Best Stocks for Investing in Generic Drugs

The generic-drug market is sizzling hot. Here are three investing ideas to catch some of that heat wave.

Investing | April 19, 2015

3 Stocks That Could Double Your Money

These three companies have the potential to double their share price from current levels. Here's why.

Investing | April 05, 2015

Can This Pharma Go From Good to Great?

Will Actavis' $66 billion merger with Allergan catapult this company from good to great? Or could a hidden risk derail this global powerhouse?

Investing | March 09, 2015

Why AbbVie Inc.'s $21 Billion Deal Had To Happen

AbbVie Inc has agreed to pay $21 billion to acquire Pharmacyclics, Inc.

Investing | February 16, 2015

Deal-Hungry Pfizer Won't Stop With Hospira; Who Could Be Next?

Pfizer recently acquired Hospira for $17 billion, but it has plenty of fuel left to go after more deals to boost its pipeline and shareholder value.

Investing | February 14, 2015

2 Small Biotech Stocks Dreaming Big in Hepatitis C

Exciting but speculative -- Industry Focus examines two companies making strides in the treatment of hepatitis C.

Investing | January 31, 2015

Big Pharma: An Up-Close Look at One Key Player

Industry Focus zooms in on restructuring, new drugs, and possible threats for pharma giant Novartis.

Investing | January 31, 2015

Can You Guess What Legal Drug Outsells the NFL?

The NFL is unquestionably one of the most successful American businesses of all-time. Surprisingly, though, the NFL's 2013 revenues were no match for this single legal drug.

Investing | January 20, 2015

Can AbbVie Inc. Overcome Humira’s Looming Patent Expiration?

AbbVie's most important product, Humira, will lose patent exclusivity in the U.S. in 2016. Should investors fear this upcoming event?

Results 1 - 10 of 432 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Healthcare